Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: ?
Life Threatening? No
Write-up: sudden death; This is a spontaneous report from a contactable physician downloaded from the Agency Regulatory Authority-WEB, regulatory authority number FR-AFSSAPS-NT20210907. A 65-year-old male patient received first dose of bnt162b2 (COMIRNATY, solution for injection, lot: EP2166), intramuscular on 10Mar2021 as single dose for covid-19 immunisation. Medical history included chronic kidney disease stage V (with hemodialysis), chronic hemodialysis, peripheral arterial occlusive disease (multi-stented PAD), ischaemic heart disease (triple coronary bypass grafting with complications) and valvular heart disease (calcified aortic stenosis tight). Concomitant medications included atorvastatin; bisoprolol; clopidogrel; sodium polystyrene sulfonate (KAYEXALATE); levothyroxine; calcium carbonate (OROCAL); pantoprazole; paracetamol; sevelamer carbonate (RENVELA); folic acid (SPECIAFOLDINE); glyceryl trinitrate (TRINITRIN); alfacalcidol (UN ALFA) and warfarin. The patient did not have Sars-CoV2 infection. The physician reported sudden death of the patient in a few minutes while preparing to come to his dialysis session on 24Mar2021. He was 14 days after a first dose of bnt162b2 and had a significant cardiovascular history. The patient died on 24Mar2021. It was unknown if autopsy was performed. No follow-up attempts are possible. No further information is expected.; Reported Cause(s) of Death: sudden death
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166